Summary
The effects of competitive (CGP 37849 and CGP 39551) and noncompetitive (dizocilpine) N-methyl-D-aspartate (NMDA) antagonists were tested in three animal models (catalepsy, sniffing, locomotion) and, in addition, the modulation of these effects by an agonist of the strychnine-insensitive glycine binding site was investigated. Both competitive and non-competitive NMDA antagonists reduced neuroleptic-induced catalepsy. Weak sniffing was induced by the competitive antagonist but strong sniffing by the non-competitive NMDA antagonist. Due to muscle relaxation the competitive antagonist reduced locomotion, in contrast to stimulation of locomotor activity induced by the noncompetitive NMDA antagonist. The glycine agonist (D-cycloserine) potentiated the effects of the non-competitive but antagonized those of the competitive NMDA antagonist.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bonhaus DW, Burge BC, McNamara JO (1987) Biochemical evidence that glycine allosterically regulates an NMDA receptor-coupled ion channel. Eur J Pharmacol 142: 489–490
Bristow DR, Bowery NG, Woodruff GN (1986) Light microscopic audiographic localisation of [3H] glycine and [3 H] strychnine binding sites in rat brain. Eur J Pharmacol 126: 303–308
Butelman ER (1990) The effect of NMDA antagonists in the radial arm maze task with an interposed delay. Pharmacol Biochem Behav 35: 533–536
Carlsson M, Carlsson A (1989a) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75: 221–226
Carlsson M, Carlsson A (1989b) Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J Neural Transm 77: 65–71
Carlsson M, Carlsson A (1990a) Interactions between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson's disease. Trends Neurosci 13: 272–276
Carlsson M, Carlsson A (1990b) The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice. Life Sci 47: 1729–1736
Carlsson M, Carlsson A (1990c) Schizophrenia: a subcortical, neurotransmitter imbalance syndrome? Schizophr Bull 16: 425–432
Chapman AG, Swan JH, Patel S, Graham JL, Meldrum BS (1990) Cerebroprotective and anticonvulsant action of competitive and non-competitive NMDA antagonists. Amino Acids: Chem Biol Med: 219–232
Clineschmidt BV, Martin GE, Bunting PR (1982a) Anticonvulsant activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine(MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2: 123–134
Clineschmidt BV, Martin GE, Bunting PR, Papp NL (1982b) Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2: 135–145
Costall B, Naylor RJ (1975) Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine. Psychopharmacologia (Berl) 43: 69–74
Davis S, Butcher SP, Morris RGM (1988) The role of NMDA receptors in certain kinds of learning. In: Cavalheiro EA, Lehmann J, Turski L (eds) Neurology and neurobiology. Frontiers in excitatory amino acids res, vol 46. Alan R Liss, New York, pp 385–392
Deutsch SI, Mastopaolo J, Schwartz BL, Rosse RB, Morihisa JM (1989) A “glutamatergic hypothesis” of schizophrenia. Clin Neuropharmacol 12: 1–13
Elliott PJ, Close SP, Walsh DM, Hayes AG, Marriott AS (1990) Neuroleptic induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists. J Neural Transm [PD-Sect] 2: 91–100
Fagg GE, Olpe HR, Pozza MF, Baud J, Steinmann M, Schmutz M, Portet C, Baumann P, Thedinga K, Bittiger H, Allgeier H, Heckendorn R, Angst C, Brundish D, Dingwall JG (1990) CGP 37849 and CGP 39551: novel and potent competitive N-methyl-Daspartate receptor antagonists with oral activity. Br J Pharmacol 99: 791–797
Foster AC, Fagg GE (1984) Acidic amino acid binding sites in mammalian neural membranes: their characteristics and relationship to synaptic receptors. Brain Res Rev 7: 103–164
Herberg LJ, Rose IC (1989) The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward. Psychopharmacology 99: 87–90
Herberg LJ, Rose IC (1990) Effects of D-cycloserine and cycloleucine, ligands for the NMDA-associated strychnine-insensitive glycine site, on brainstimulation reward and spontaneous locomotion. Pharmacol Biochem Behav 36: 735–738
Hood WF, Compton RP, Monhan JB (1989) D-cycloserine: a ligand for the N-methyl-Daspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 98: 91–95
Imperato A, Scrocco MG, Bacchi S, Angelucci L (1990) NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur J Pharmacol 187: 555–556
Johnson JW, Ascher P (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325: 529–531
Johnson KM, Jones SM (1990) Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 30: 707–750
Kelly PH, Seviour PW, Iversen SD (1975) Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 94: 507–522
Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20: 379–382
Kleckner NW, Dingledine R (1988) Requirement for glycine in activation of NMDAreceptors expressed in Xenopus oocytes. Science 241: 835–837
Koek W, Woods JH, Ornstein P (1987) A simple and rapid method for assessing similarities among directly observable behavioral effects of drugs: PCP-like effects of 2-amino-5-phosphonovalerate in rats. Psychopharmacology 91: 297–304
Kornhuber J, Kornhuber ME (1986) Presynaptic dopaminergic modulation of cortical input to the striatum. Life Sci 39: 669–674
Kornhuber J, Mack-Burkhardt F, Riederer P, Hebenstreit GF, Reynolds GP, Andrews HB, Beckmann H (1989) [3 H] MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 77: 231–236
Monaghan DT, Holets VR, Toy DW, Cotman CW (1983) Anatomical distributions of four pharmacologically distinct 3H-L-glutamate binding sites. Nature 306: 176–178
Monaghan DT, Cotman CW (1985) Distribution of N-methyl-D-aspartate-sensitive L-[3H]-glutamate-binding sites in rat brain. J Neurosci 5: 2909–2919
Monaghan DT, Olverman HJ, Nguyen L, Watkins JC, Cotman CW (1988) Two classes of N-methyl-D-aspartate recognition sites: differential distribution of differential regulation by glycine. Proc Natl Acad Sci USA 85: 9836–9840
Monaghan DT, Bridges RJ, Cotman CW (1989) The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29: 365–402
Monahan JB, Handelmann GE, Hood WF, Cordi AA (1989) D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol Biochem Behav 34: 649–653
Morris RGM, Hagan JJ, Rawlins JNP (1986) Allocentric spatial learning by hippocampectomised rats: a further test of the “spatial mapping” and “working memory” theories of hippocampal functions. Quart J Exp Psychol 388: 257–281
Olney JW (1990) Phencyclidine, dizocilpine, and cerebrocortical neurons. Science 247: 221
Randrup A, Munkvad I (1966) Role of catecholamines in the amphetamine excitatory response. Nature 211: 540
Reynolds IJ, Murphy SN, Miller RJ (1987) 3H-labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc Natl Acad Sci USA 84: 7744–7748
Reynolds IJ, Miller RJ (1988) Multiple sites for the regulation of the N-methyl-D-aspartate receptor. Mol Pharmacol 33: 581–584
Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG, Deutsch SI (1989) Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label pilot study. Clin Neuropharmacol 12: 416–424
Rosse RB, Schwartz BL, Leighton MP, Davis RE, Deutsch SI (1990) An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy. Clin Neuropharmacol 13: 348–354
Scheel-Krüger (1986) Dopamine-GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system. Acta Neurol Scand 73/107
Schmidt WJ (1986) Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. Psychopharmacology 90: 123–130
Schmidt WJ, Bubser M (1989) Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32: 621–623
Schmidt WJ, Bubser M, Hauber W (1990) Anticataleptic effects of NMDA receptor antagonists. Eur J Neurosci [Suppl 3]: 118
Schmutz M, Portet C, Jeker A, Klebs K, Vassout A, Allgeier H, Heckendorn R, Fagg GE, Olpe HR, van Riezen H (1990) The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent orally-active anticonvulsants in rodents. Naunyn Schmiedebergs Arch Pharmacol 342: 61–66
Sherman AD, Davidson AT, Baruah S, Hegwood TS, Waziri R (1991) Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett 121: 77–80
Tiedtke PI, Bischoff C, Schmidt WJ (1990) MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm 81: 173–182
Watson GB, Bolanowski MA, Boganoff MP, Deppeler CL, Lanthorn TH (1990) D-cycloserine acts as partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 510: 158–160
Waziri R (1988) Glycine therapy of schizophrenia. Biol Psychiatry 23: 209–214
Willetts J, Balster RL, Leander JD (1991) The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 11: 423–428
Wong EHF, Knight AR, Ransom R (1987) Glycine modulates [3H]MK-801 binding to the NMDA receptor in rat brain. Eur J Pharmacol 142: 487–488
Zukin SR, Zukin RS, Vale W, Rivier J, Nichthauser R, Snell LD, Johnson KM (1987) An endogenous ligand of the brain σ/PCP receptor antagonizes NMDA-induced neurotransmitter release. Brain Res 416: 84–89
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kretschmer, B.D., Zadow, B., Volz, T.L. et al. The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior. J. Neural Transmission 87, 23–35 (1992). https://doi.org/10.1007/BF01253108
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01253108